

205–1810. General information concerning the Commission may also be obtained by accessing its Internet server (<http://www.usitc.gov>). The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at <http://edis.usitc.gov>.

**SUPPLEMENTARY INFORMATION:** The Commission instituted this investigation on April 9, 2001, based on a complaint filed by Proxim, Inc. ("Proxim") against 14 respondents. Three companies subsequently intervened, including Agere Systems Inc. ("Agere"). In its complaint, Proxim contended that respondents' accused products infringed the patent claims in issue because they contained either semiconductors made by intervenor Agere ("the Agere parties") or by respondent Intersil Corp. ("the Intersil parties").

On September 25, 2002, the Commission determined not to review an ID by the then presiding ALJ terminating the investigation as to the Agere parties on the basis of a settlement agreement. Only the Intersil parties then remained in the investigation.

On March 17, 2003, Proxim and Intersil entered into a settlement agreement. On May 5, 2003, Proxim and the Intersil parties filed a joint motion to terminate the investigation on the basis of the settlement agreement. The Commission investigative attorney supported the joint motion.

On May 15, 2003, the current presiding ALJ issued the subject ID (Order No. 106) granting the joint motion of Proxim and the Intersil parties to terminate the investigation on the basis of a settlement agreement. No party filed a petition to review the ID.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in § 210.42 of the Commission's rules of practice and procedure (19 CFR § 210.42).

Issued: June 11, 2003.

By order of the Commission.

**Marilyn R. Abbott,**

*Secretary.*

[FR Doc. 03–15250 Filed 6–16–03; 8:45 am]

**BILLING CODE 7020–02–P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—IMS Global Learning Consortium, Inc.

Notice is hereby given that, on May 27, 2003, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), IMS Global Learning Consortium, Inc. has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership status. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Artesia Technologies, Rockville, MD has been dropped as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and IMS Global Learning Consortium, Inc. intends to file additional written notification disclosing all changes in membership.

On April 7, 2000, IMS Global Learning Consortium, Inc. filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on September 13, 2000 (65 FR 55283).

The last notification was filed with the Department on March 5, 2003. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on March 27, 2003 (68 FR 15004).

**Constance K. Robinson,**

*Director of Operations, Antitrust Division.*

[FR Doc. 03–15181 Filed 6–16–03; 8:45 am]

**BILLING CODE 4410–11–M**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—Semiconductor Test Consortium, Inc.

Notice is hereby given that, on May 27, 2003, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Semiconductor Test Consortium, Inc. has filed written notifications simultaneously with the

Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to section 6(b) of the Act, the identities of the parties are Advantest Corporation, Tokyo, JAPAN; Intel Corporation, Chandler, AZ; and Motorola, Inc., Austin, TX. The nature and objectives of the venture are to administer the development, support and promotion of the specifications of Open Semiconductor Test Architecture ("OPENSTAR"), a testing standard which defines a flexible testing platform for complex logic devices for use in the semiconductor and automated test equipment industries. The mission of Semiconductor Test Consortium, Inc. is to support the development and long-term success of OPENSTAR, including the delivery of technical and economic performance sustainability, open architecture, and multi-vendor interoperability at both the hardware and software levels. Semiconductor Test Consortium, Inc. shall achieve this mission by developing and promoting its open architecture specifications as industry-wide standards, issuing design guidelines relating to its specifications, presenting activities that promote the use of the specifications, and providing for the licensing or publication of the specifications on reasonable and non-discriminatory terms to both members and non-members alike.

**Constance K. Robinson,**

*Director of Operations, Antitrust Division.*

[FR Doc. 03–15182 Filed 6–16–03; 8:45 am]

**BILLING CODE 4410–11–M**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated January 27, 2003, and published in the **Federal Register** on February 6, 2003 (68 FR 6181), AccuStandard, Inc., 125 Market Street, New Haven, Connecticut 06513, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
Aminorex (1585) .....	I
Gamma hydroxybutyric acid (2010) .....	I
Methaqualone (2565) .....	I
Ibogaine (7260) .....	I
Lysergic acid diethylamide (7315) .....	I
Tetrahydrocannabinols (7370) .....	I
Mescaline (7381) .....	I
4-Bromo-2, 5-dimethoxyamphetamine (7391) .....	I
4-Bromo-2, 5-dimethoxyphenethylamine (7392) .....	I
4-Methyl-2, 5-dimethoxyamphetamine (7395) .....	I
2, 5-Dimethoxyamphetamine (7396) .....	I
3, 4-Methylenedioxyamphetamine (7400) .....	I
N-Hydroxy-3, 4-methylenedioxyamphetamine (7402) .....	I
3, 4-Methylenedioxy-N-ethylamphetamine (7404) .....	I
3, 4-Methylenedioxymethamphetamine (7405) .....	I
4-Methoxyamphetamine (7411) .....	I
Bufotenine (7433) .....	I
1-[1-(2-Thienyl) cyclohexyl]piperidine (7470) .....	I
Codeine-N-oxide (9053) .....	I
Dihydromorphine (9145) .....	I
Heroin (9200) .....	I
Morphine-N-oxide (9307) .....	I
Normorphine (9313) .....	I
Etonitazene (9624) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Phenmetrazine (1631) .....	II
Methylphenidate (1724) .....	II
Amobarbital (2125) .....	II
Pentobarbital (2270) .....	II
Secobarbital (2315) .....	II
Glutethimide (2550) .....	II
Phencyclidine (7471) .....	II
Alphaprodine (9010) .....	II
Anileridine (9020) .....	II
Cocaine (9041) .....	II
Codeine (9050) .....	II
Diprenorphine (9058) .....	II
Dihydrocodeine (9120) .....	II
Hydromorphone (9150) .....	II
Diphenoxylate (9170) .....	II
Benzoyllecgonine (9180) .....	II
Ecgonine (9180) .....	II
Hydrocodone (9193) .....	II
Levorphanol (9220) .....	II
Methadone (9250) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Opium, raw (9600) .....	II
Opium tincture (9630) .....	II
Opium powdered (9639) .....	II
Levo-alphaacetylmethadol (9648) .....	II
Oxymorphone (9652) .....	II
Alfentanil (9737) .....	II
Sufentanil (9740) .....	II
Fentanyl (9801) .....	II

The firm plans to manufacture small quantities of the listed controlled substances to make reference standards.

No comments or objections have been received. DEA has considered the factors in title 21, United States code, section 823(a) and determined that the registration of AccuStandard, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has

investigated AccuStandard, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted

Dated: June 6, 2003.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 03-15203led 6ndash;16ndash;03; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated January 27, 2003, and published in the **Federal Register** on February 6, 2003, (68 FR 6182), American Radiolabeled Chemicals, Inc., 11624 Bowling Green Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	schedule
Gamma hydroxybutyric acid (2010).	I
Lysergic acid diethylamide (7315).	I
Dimethyltryptamine (7435) .....	I
Dihydromorphine (9145) .....	I
Phencyclidine (7471) .....	II
Cocaine (9041) .....	II
Codeine (9050) .....	II
Hydromorphone (9150) .....	II
Oxycodone (9143) .....	II
Thebaine (9333) .....	II
Benzoylcgonine (9180) .....	II
Meperidine (9230) .....	II
Metazocine (9240) .....	II
Morphine (9300) .....	II
Oxymorphone (9652) .....	II

The firm plans to bulk manufacture small quantities of the listed controlled substances as radiolabeled compounds.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of American Radiolabeled Chemicals, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated American Radiolabeled Chemicals, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of

Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: June 4, 2003.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 03-15194 Filed 6-16-03; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Registration**

By Notice dated August 20, 2002, and published in the **Federal Register** on August 29, 2002, (67 FR 55430), Applied Science Labs, Inc., A Division of Alltech Associates, Inc., 2701 Carolean Industrial Drive, State College, Pennsylvania 16801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Heroin (9200) .....	I
Cocaine (9041) .....	II
Codeine (9050) .....	II
Meperidine (9230) .....	II
Methadone (9250) .....	II
Morphine (9300) .....	II

The firm plans to import these controlled substances for the manufacture of reference standards.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Applied Science Labs, Inc. to import the listed controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Applied Science Labs, Inc. on a regular basis to ensure that the company's continued registration is consistent with the public interest. This investigation included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title

21, Code of Federal Regulations, Section 1301.34, the above firm is granted registration as an importer of the basic classes of controlled substances listed above.

Dated: June 4, 2003.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 03-15196 Filed 6-16-03; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated February 5, 2003, and published in the **Federal Register** on February 12, 2003, (68 FR 7147), Cedarburg Pharmaceuticals, LLS 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Tetrahydrocannabinols (7370) ...	I
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Hydrocodone (9193) .....	II

The firm plans to manufacture the listed controlled substances for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Cedarburg Pharmaceuticals, LLC, to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Cedarburg Pharmaceuticals, LLC, to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.